← Leaderboards
Scott M. Dehm
University Of Minnesota
$10,389,676
Attributed
$14,649,400
Total exposure
11
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,649,400 · 11
By mechanism
R01$13,755,111 · 6
T32$505,869 · 1
R21$365,420 · 1
R13$23,000 · 3
Top collaborators
- Andrew J Armstrong5 shared
- Susan Halabi5 shared
- Marja T Nevalainen4 shared
- Joshua Michael Lang3 shared
- Carol Ann Lange1 shared
- Jill M Siegfried1 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Dawn A Lowe$11,277,186
- Alistair McGregor$8,487,942
- Haojie Huang$10,928,769
- Micah Gearhart$425,104
Others in their field
Top investigators on “Malignant Neoplasm Of Prostate”
- David Heimbrook · Leidos Biomedical Research, Inc.$255,843,614
- Leonard Freedman · Leidos Biomedical Research, Inc.$63,277,106
- Walter John Curran · Thomas Jefferson University$61,298,085
- Norman Wolmark · Nsabp Foundation, Inc.$54,888,134
- James J. Dignam · University Of Chicago$48,310,409
- Laurence H Baker · University Of Michigan At Ann Arbor$43,366,962
Research focus
Malignant Neoplasm Of ProstateResistancePhenotypeAndrogen ReceptorTargeted TreatmentTumorAndrogensCessation Of LifeVariantMalignant NeoplasmsLigand Binding DomainAbirateroneGrowthBiological MarkersGenetic TranscriptionGenerationsCastrationAutomobile DrivingAr GeneHormone TherapyResistance MechanismResponseProstate Cancer CellCancer Patient
Grant awards (35)
Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic niches$651,191
R01 · FY2025 · CA
Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC$647,291
R01 · FY2025 · CA
Pharmacological Jak2 inhibition to overcome androgen receptor aberrations in prostate cancer$597,173
R01 · FY2025 · CA
Molecular, Genetic and Cellular Targets of Cancer Training Program$505,869
T32 · FY2025 · CA · contact PI
Targeting early events in prostate cancer lineage plasticity$455,926
R01 · FY2025 · CA · contact PI
AR Gene Rearrangements and AR Signaling in Prostate Cancer$403,130
R01 · FY2025 · CA · contact PI
2025 Hormone-Dependent Cancers Gordon Research Conference and Gordon Research Seminar$8,000
R13 · FY2025 · CA · contact PI
Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic niches$625,914
R01 · FY2024 · CA
Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC$612,180
R01 · FY2024 · CA
Pharmacological Jak2 inhibition to overcome androgen receptor aberrations in prostate cancer$564,525
R01 · FY2024 · CA
Targeting early events in prostate cancer lineage plasticity$437,922
R01 · FY2024 · CA · contact PI
AR Gene Rearrangements and AR Signaling in Prostate Cancer$382,974
R01 · FY2024 · CA · contact PI
Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic niches$695,050
R01 · FY2023 · CA
Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC$636,857
R01 · FY2023 · CA
Pharmacological Jak2 inhibition to overcome androgen receptor aberrations in prostate cancer$559,451
R01 · FY2023 · CA
Targeting early events in prostate cancer lineage plasticity$486,808
R01 · FY2023 · CA · contact PI
AR Gene Rearrangements and AR Signaling in Prostate Cancer$403,130
R01 · FY2023 · CA · contact PI
Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC$632,590
R01 · FY2022 · CA
Pharmacological Jak2 inhibition to overcome androgen receptor aberrations in prostate cancer$576,689
R01 · FY2022 · CA
AR gene rearrangements and AR signaling in prostate cancer$356,629
R01 · FY2022 · CA · contact PI
AR gene rearrangements and AR signaling in prostate cancer$363,908
R01 · FY2021 · CA · contact PI
Society for Basic Urologic Research 2020 Annual Meeting: CELLULAR INTERACTIONS AND IDENTITIES IN UROLOGIC BIOLOGY$10,000
R13 · FY2021 · DK · contact PI
Clinical genomic predictive model of first line androgen receptor inhibitor therapy outcomes in men with mCRPC$653,173
R01 · FY2020 · CA
mRNA Polyadenylation in Prostate Cancer$385,840
R01 · FY2020 · CA · contact PI
AR gene rearrangements and AR signaling in prostate cancer$363,908
R01 · FY2020 · CA · contact PI
AR gene rearrangements and AR signaling in prostate cancer$349,836
R01 · FY2019 · CA · contact PI
AR gene rearrangements and AR signaling in prostate cancer$366,539
R01 · FY2018 · CA · contact PI
8th Great Lakes Nuclear Receptors Conference (GLNRC)$5,000
R13 · FY2018 · CA · contact PI
AR Gene Rearrangements and AR Signaling in Prostate Cancer$310,149
R01 · FY2017 · CA · contact PI
AR Gene Rearrangements and AR Signaling in Prostate Cancer$310,251
R01 · FY2016 · CA · contact PI
AR Gene Rearrangements and AR Signaling in Prostate Cancer$310,352
R01 · FY2015 · CA · contact PI
AR Gene Rearrangements and AR Signaling in Prostate Cancer$305,177
R01 · FY2014 · CA · contact PI
AR Gene Rearrangements and AR Signaling in Prostate Cancer$310,548
R01 · FY2013 · CA · contact PI
AR Transcriptional Activation Domains in Prostate Cancer Progression$199,320
R21 · FY2010 · CA · contact PI
AR Transcriptional Activation Domains in Prostate Cancer Progression$166,100
R21 · FY2009 · CA · contact PI